Pharmaceuticals, Biotechnology and Life Sciences
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.
Sanofi and Regeneron Pharmaceuticals, on Friday announced that the European Medicine Agency`s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Dupixent.
Realm Therapeutics has won FDA’s approval for its IND application to proceed with Phase II clinical trial for atopic dermatitis (AD) drug.
U.S. Food and Drug Administration (FDA) has approved Pfizer’s Eucrisa (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor…